Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 16/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018507 | 1.00 | CCR1 (0.52) | CCR1MEN1KMT2ADRD2STS | |
| SCHEMBL652941 | 0.90 | CCR1 (0.62) | CCR1NR1I2 | |
| SCHEMBL2160379 | 0.88 | CCR1 (0.49) | CCR1MEN1KMT2ADRD2STS | |
| SCHEMBL654564 | 0.86 | CCR1 (0.48) | CCR1MEN1KMT2ADRD2STS | |
| SCHEMBL652739 | 0.86 | CCR1 (0.47) | CCR1MEN1KMT2ADRD2STS | |
| SCHEMBL654948 | 0.85 | CCR1 (0.50) | CCR1MEN1KMT2ADRD2STS | |
| SCHEMBL655150 | 0.84 | DRD2 (0.56) | CCR1MEN1KMT2ADRD2STS | |
| SCHEMBL652654 | 0.83 | CCR1 (0.47) | CCR1MEN1KMT2ADRD2NR1I2 | |
| SCHEMBL3026041 | 0.82 | CCR1 (0.50) | CCR1 | |
| SCHEMBL557597 | 0.81 | DRD2 (0.61) | CCR1MEN1KMT2ADRD2STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173713-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2173713-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2582670-B1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8642622-B2 | Piperidinyl compound as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642622-B2 | Piperidinyl compound as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642622-B2 | Piperidinyl compound as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8501782-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501782-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501782-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2582670-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
| WO-2011159852-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20100204274-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204274-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204274-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| EP-2173713-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009015164-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015164-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204274-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CXCR1, CCR1 | CCR1 3/4885MEN1 2813/4885KMT2A 2401/4885 |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCL11 | CCR1 6/4885MEN1 4450/4885KMT2A 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.